There has been a lot of debate about national pharmacare coverage of catastrophic drug costs in government, the media, and among health policy experts, yet patients— who will be the ones most affected—have rarely had their say.
To get a better understanding of what patients value in terms of a national drug coverage program The Cameron Institute commissioned Ward Health to survey patient advocacy organizations throughout Canada. Nearly 40 national associations responded to the survey. This is what we learned.